title: Effects of prenylamine and AQ-A 39 on reentrant ventricular arrhythmias induced during the late myocardial infarction period in conscious dogs.
abstract: The effects of prenylamine (PNL) and AQ-A 39 on sustained ventricular tachycardia (SVT) were studied by programmed stimulation in conscious dogs 4-10 days after ligation of the left anterior descending (LAD) coronary artery. In 8 of 16 dogs developing SVT in the control, PNL (3 mg/kg intravenously, i.v.) suppressed inducibility of SVT and slowed the rate of tachycardia in 6 other animals. In a separate group of 10 dogs with inducible SVT, AQ-A 39 (4 mg/kg i.v.) abolished elicitation of tachycardia in 3 dogs and decreased its rate in 6 other dogs. Neither drug affected normal conduction significantly, but PNL impaired slow conduction in the infarct zone, as indicated by prolongation of late potential. Both agents increased the effective refractory period (ERP) of infarcted and normal ventricular myocardium and prolonged the corrected QT interval. PNL and AQ-A 39 exert notable efficacy in preventing infarcted heart from severe ventricular arrhythmias. Prolongation of ventricular refractoriness and repolarization, as well as decreased slow conduction in ischemically damaged myocardium, are major mechanisms accounting for the effectiveness of these drugs against ventricular arrhythmias.
authors.affiliation: Department of Cardiology, University of Heidelberg, Germany.
authors.forename: I
authors.initials: I
authors.lastname: Aidonidis
authors.forename: E
authors.initials: E
authors.lastname: Egel
authors.forename: T
authors.initials: T
authors.lastname: Hilbel
authors.forename: W
authors.initials: W
authors.lastname: Kuebler
authors.forename: J
authors.initials: J
authors.lastname: Brachmann
mesh_terms: D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004285:Dogs; D004562:Electrocardiography / Q000187:drug effects; D004594:Electrophysiology; D007275:Injections, Intravenous; D054833:Isoindoles; D009203:Myocardial Infarction / Q000150:complications*; D010797:Phthalimides / Q000494:pharmacology / Q000627:therapeutic use*; D011299:Prenylamine / Q000494:pharmacology / Q000627:therapeutic use*; D017180:Tachycardia, Ventricular / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000889:Anti-Arrhythmia Agents; D054833:Isoindoles; D010797:Phthalimides; D011299:Prenylamine; C030532:falipamil